ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ziftomenib

Also written as “Ziftomenib”.

Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Gastrointestinal Stromal Tumors · Hematologic Neoplasms, led by 2 companies.

Drug pageZiftomenib: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 16, 20256 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kura Oncology55 open or runningphase 3since May 16, 2025Jun 25, 2019Dec 2026phase 1 · NCT06001788
Kyowa Kirinits history only11 open or runningphase 2since Apr 8, 2026Apr 8, 2026Mar 2027phase 2 · NCT07623616

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kura Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2019First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04067336 · 263 enrolled · United States, Belgium, Canada and more
  2. Jul 28, 2021Named ziftomenibINNProposed as its International Nonproprietary Name in WHO's List 125
  3. Aug 7, 2023Phase 1 study in Hematologic NeoplasmsNCT06001788 · 171 planned · United States, Italy, Spain
  4. Oct 14, 2024Phase 1 study in Gastrointestinal Stromal TumorsNCT06655246 · 135 planned · United States
  5. May 16, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT07007312 · 1,300 planned · United States, Australia, Belgium and more
  6. Oct 21, 2026Phase 1 study in Myelodysplastic SyndromesNCT07929740 · 126 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Hematologic NeoplasmsNCT06001788
  2. Oct 16, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04067336
  3. Feb 28, 2029Primary completion: phase 1 study in Myelodysplastic SyndromesNCT07929740
  4. Jun 2029Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT06655246

TargetBeta

KMT2A →read by rule
“An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, ”NCIt, by rule

Other programs on KMT2A

ProgramCompanyFurthest phaseStudies
revumenibruleSyndax Pharmaceuticalsphase 36
bleximenibJohnson & Johnsonphase 34
icovamenibrulebiomea-fusion-incphase 27

Studies

All 5 Kura Oncology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07929740Myelodysplastic Syndromes1Not yet recruitingFeb 28, 2029126
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingNov 20311,300
NCT06655246Gastrointestinal Stromal Tumors · United States1RecruitingJun 2029135
NCT06001788Hematologic Neoplasms · United States, Italy, Spain1RecruitingDec 2026171
NCT04067336Leukemia, Myeloid, Acute · United States, Belgium, Canada and more2Active, not recruitingOct 16, 2028263

How it is read

Names in the registry

  • “Ziftomenib”, 7 entries
  • “ziftomenib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.